Source: Patient Worthy Challenges Unique to Cell and Gene Therapies (CGTx) Clinical Trials Cell and gene therapies (CGTx) have emerged as a novel and advanced
Delays in clinical trials, worsened by the Inflation Reduction Act (IRA), are now a challenge to patient access to new therapies. Evolving complex regulatory requirements,
Innovative technologies have revolutionized how clinical trials are conducted, catering to a diverse range of participants while ensuring patient-centricity remains a top priority. Embracing decentralized
Clinical trial sponsors need reliable patient data to ensure compliance and adhere to the regional and national guidelines. While the complexities persist in clinical trials,
The need for greater patient engagement isn’t a new issue today. It has persisted for decades, and the struggle to optimize it is still a
Source: Telehealth and Medicine Today Clinical trials, the bedrock of medical research, are facing a pervasive challenge that threatens the very foundation of therapeutic development:
Source: Healthcare Business Today In the fast-evolving healthcare industry, the quest for innovative therapies is often hindered by formidable obstacles, chief among them being the
Source: HealthIT Answers The landscape of drug development is fraught with escalating costs and formidable challenges. Lengthy timelines, exorbitant expenses, and regulatory hurdles often impede
Source: Rare Disease and Orphan Drug Journal Abstract One of the main challenges in rare diseases is the unavailability of reliable estimates of prevalence and
Source: Pharmaceutical Outsourcing In the fast-paced world of biopharmaceuticals, emerging and mid-market companies face significant challenges when bringing innovative drugs to market. One major obstacle
Jeeva Clinical Trials Inc.
